Topics

FDA speeds up review for Tesaro's ovarian cancer drug niraparib

05:53 EDT 10 Jul 2019 | SmartBrief

The experimental drug Zejula, or niraparib, being developed by Tesaro, a GlaxoSmithKline subsidiary, will undergo fast-track  -More

Original Article: FDA speeds up review for Tesaro's ovarian cancer drug niraparib

NEXT ARTICLE

More From BioPortfolio on "FDA speeds up review for Tesaro's ovarian cancer drug niraparib"

Quick Search

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

GlaxoSmithKline
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...